ERBB2 and breast carcinoma: A recent randomized phase II ATTEMPT trial compared the combination of trastuzumab and weekly paclitaxel to antibody–drug conjugate trastuzumab emtansine (T-DM1) in women with stage I HER2 positive breast cancer.